ERBB2 and breast cancer: This trend was similar in luminal HER2-negative tumors (luminal A and luminal B); however, interval BC or screening non-attendance did not translate to an increased risk of death among patients with HER2-positive (luminal B and non-luminal) and triple-negative BCs compared to screen-detected BCs.